Abstract
Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Current Gene Therapy
Title: The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Volume: 1 Issue: 1
Author(s): J. S. Norris, M. L. Hyer, C. Voelkel-Johnson, S. L. Lowe, S. Rubinchik and J-Y. Dong
Affiliation:
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Abstract: Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Export Options
About this article
Cite this article as:
Norris S. J., Hyer L. M., Voelkel-Johnson C., Lowe L. S., Rubinchik S. and Dong J-Y., The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer, Current Gene Therapy 2001; 1 (1) . https://dx.doi.org/10.2174/1566523013348977
DOI https://dx.doi.org/10.2174/1566523013348977 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain
Current Pharmaceutical Design Impact of the Somatotrope Growth Hormone (GH)/Insulin-Like Growth Factor 1 (IGF-1) Axis Upon Thymus Function: Pharmacological Implications in Regeneration of Immune Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Targeting Calmodulin in Reversing Multi Drug Resistance in Cancer Cells
Mini-Reviews in Medicinal Chemistry Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers
Current Pharmaceutical Biotechnology A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Recent Patents on Biotechnology Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry 10 Years of SELDI: What Have we Learnt?
Current Proteomics In Search of Novel and Therapeutically Significant Melatoninergic Ligands
Recent Patents on CNS Drug Discovery (Discontinued) The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
Current Radiopharmaceuticals The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine